PRMT5 and neoplasm: In this study, we demonstrated that the triple combination of a PRMT5 inhibitor, CPT‐11, and αTIGIT exhibited superior anti‐tumor efficacy with minimal toxic side effects, and this synergistic effect successfully reactivated T cell immunity.